Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abeona TherapeuticsABEO -1.46%30 3-Year Book Growth Rate is 24.20% as of Jun. 2026. GuruFocus rates ABEO with a GF Score™ of 30/100. The stock has 5 warning signs investors should review. Among 1,123 Biotechnology companies, Abeona Therapeutics ranks better than 86.11% on this metric.
During the past 12 months, Abeona Therapeutics's average Book Value per Share Growth Rate was -29.90% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 24.20% per year.
During the past 5 years, the average Book Value per Share Growth Rate was -40.40% per year.
During the past 10 years, the average Book Value per Share Growth Rate was -39.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Abeona Therapeutics was 146.80% per year. The lowest was -72.40% per year. And the median was -4.20% per year.
Abeona Therapeutics (NAS:ABEO) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Abeona Therapeutics 3-Year Book Growth Rate Related Terms
ABEO vs STRO, IKT, AGEN: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, Abeona Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abeona Therapeutics 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Abeona Therapeutics's 3-Year Book Growth Rate falls into.
Abeona Therapeutics 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 24.20% mean?
Abeona Therapeutics (ABEO) has a 3-Year Book Growth Rate of 24.20% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Abeona Therapeutics and its competitors. According to the industry distribution chart, Abeona Therapeutics ranks #156 out of 1123 companies in the Biotechnology industry, placing it in the top 13.9%.
Is Abeona Therapeutics' 3-Year Book Growth Rate too high?
Abeona Therapeutics' current 3-Year Book Growth Rate is 24.20%. Based on the distribution chart, Abeona Therapeutics ranks #156 out of 1123 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Abeona Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Abeona Therapeutics' 3-Year Book Growth Rate compare to STRO and IKT?
According to the Biotechnology industry distribution chart, Abeona Therapeutics ranks #156 out of 1123 companies for 3-Year Book Growth Rate. This places Abeona Therapeutics in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Abeona Therapeutics and its competitors. Abeona Therapeutics's current 3-Year Book Growth Rate is 24.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abeona Therapeutics stock overvalued right now?
Abeona Therapeutics (ABEO) has a current 3-Year Book Growth Rate of 24.20%. The current 3-Year Book Growth Rate is 24.20%. Abeona Therapeutics' overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Abeona Therapeutics (ABEO), the current 3-Year Book Growth Rate is 24.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
30GF Score
Get the complete analysis for ABEO
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABEO has been successfully added to your 
